2018 Annual Report next
Building a Leading Oncology Franchise
Our portfolio contains four clinical-stage oncology candidates, including pracinostat in an ongoing global registration trial, and ME-401 starting a Phase 2 clinical trial to support accelerated approval of a marketing application with the FDA.
Differentiated Candidates Addressing Clear Needs
We strive to select drug candidates against validated targets with the goal of developing medicines that are differentiated and address clear medical needs to deliver improved benefit to patients either as standalone treatments or in combination with other medicines.
Strong Financials, Optimally Building Value
We finished fiscal year 2018 in our strongest financial position ever with $102.7 million in cash, cash equivalents and short-term investments, leaving us well positioned to strategically and efficiently allocate resources to advance and commercialize our drug candidates independently or via partnership to optimally build value.